Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 66, Issue 9, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.00658-22
Keywords
TBI-166; tuberculosis; murine model; BALB/c mice; C3HeB/FeJ mice; regimen
Categories
Funding
- National Natural Science Foundation of China [82173862]
- Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support [ZYLX202123]
Ask authors/readers for more resources
TBI-166, derived from riminophenazine analogues, is a more potent anti-TB drug than clofazimine and is currently being tested in a phase IIa clinical trial in China. The results of this study demonstrate the superior efficacy of the TBI-166+BDQ+PZA regimen in treating murine TB models, compared to other regimens such as HRZ, TBI-166+BDQ+LZD, and BPaL. These findings suggest that TBI-166, in combination with BDQ and PZA, could be a promising treatment option for drug-resistant TB and should be further evaluated in phase IIb clinical trials.
TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China. Preclinical regimen studies containing TBI-166 will support the phase IIb clinical trials of TBI-166. In the present study, we compared the efficacy in three murine TB models of an all-oral drug-resistant TB drug regimen of TBI-166 with bedaquiline (BDQ) and pyrazinamide (PZA) with the first-line regimen of isoniazid (INH) with rifampin (RFP) and PZA (HRZ regimen), the most effective reported TBI-166-containing regimen of TBI-166 with BDQ and linezolid (LZD), and the Nix-TB clinical trial regimen of BDQ with pretomanid and LZD (BPaL regimen). In the C3HeB/FeJ murine TB model, for the TBI-166+BDQ+PZA regimen, the lungs of mice were culture negative at 4 weeks, and there were no relapses at 8 weeks of treatment. The reduction in bacterial burden and relapse rate were greater than those of the HRZ regimen and the TBI-166+BDQ+LZD regimen. Compared with the BPaL regimen, the TBI-166+BDQ+PZA regimen had similar or stronger early bactericidal activity, bactericidal activity, and sterilizing activity in the BALB/c murine TB model. The bacterial burden in the TBI-166+BDQ+PZA regimen group decreased significantly more than that in the BPaL regimen group and was almost or totally relapse free (<13.33% after 8 weeks). In conclusion, oral short-course three-drug regimens, including TBI-166 with high efficacy, were identified. The TBI-166+BDQ+PZA regimen is recommended for further study in a TBI-166 phase IIb clinical trial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available